Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial

Abstract We report on the randomized portion of the phase 2, open-label CheckMate 650 trial (NCT02985957), in which docetaxel-experienced, biologically male patients with chemotherapy-refractory metastatic castration-resistant prostate cancer were randomized 2:2:1:2 to nivolumab 3 mg /kg plus ipilim...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Padmanee Sharma, Michael Krainer, Fred Saad, Daniel Castellano, Jens Bedke, Mariusz Kwiatkowski, Akash Patnaik, Giuseppe Procopio, Paweł Wiechno, Samith Kochuparambil, Christian Thomas, José Ángel Arranz Arija, Steven L. McCune, Steinbjørn Hansen, Gedske Daugaard, Juan Ignacio Delgado Mingorance, Craig Kukard, Sumit K. Subudhi, Sreyashi Basu, Sonali Jindal, Bilal A. Siddiqui, Ana Lako, Saurabh Gupta, Viktor Fedorov, Neha P. Amin, Arancha Campos, Yumeng Wang, Justin M. David, Russell K. Pachynski
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Nature Portfolio 2026-05-01
סדרה:	Nature Communications
גישה מקוונת:	https://doi.org/10.1038/s41467-026-72242-w
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!